Andy Hsieh

Stock Analyst at William Blair

(2.90)
# 1,475
Out of 5,124 analysts
14
Total ratings
62.5%
Success rate
43.23%
Average return

Stocks Rated by Andy Hsieh

Aardvark Therapeutics
Dec 12, 2025
Initiates: Outperform
Price Target: n/a
Current: $13.13
Upside: -
Terns Pharmaceuticals
Nov 3, 2025
Upgrades: Outperform
Price Target: n/a
Current: $40.40
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.14
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.75
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.61
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $69.55
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $13.23
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $28.93
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.15
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $66.55
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $8.78
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $1.36
Upside: -